Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$768.1MCash on Hand
70.8mo Cash Runway
Follow AMLX by emailGet an email when AMLX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AMLX, unsubscribe in one click. Privacy
📣 What AMLX Says Is Next
by the end of 2026 · “Amylyx remains on track to submit a New Drug Application to the FDA by the end of 2026 .”
Company press release, Nov 5, 2026 · SEC filing
by year-end · Avexitide: “We remain on track to submit our NDA by year-end and are executing on our comprehensive commercial readiness plans ahead of a potential launch of avexitide in 2027, if approved.”
Company press release, Nov 5, 2026 · SEC filing
by the end of 2026 · “Our NDA submission readiness is well underway, and we continue to advance our preparations for a potential commercial launch of avexitide in 2027, if approved.” Amylyx plans to submit a New Drug Application (NDA) to the FDA by the end of 2026.”
Company press release, Aug 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings Reported Q3 2026 net loss of $45.5 million ($0.38 per share) and cash of $768.1 million after about $544.6 million in net offering proceeds. Positive Phase 3 LUCIDITY topline data for avexitide and NDA submission on track for year-end. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 8, 2026 ·
Deal Amylyx entered a Manufacturing and Supply Agreement with Bachem Americas on September 8, 2026, and a term sheet with Polypeptide Group AG on September 1, 2026, for long-term avexitide drug substance supply if approved. Polypeptide term sheet includes a $30 million upfront capacity fee. Minimum purchases begin in 2028. Form 8-K · SEC filing
Aug 20, 2026 ·
Financing Amylyx is offering 14,090,000 shares of common stock at a public offering price of $35.50 per share, with gross proceeds of $500,195,000 before underwriting discounts. Underwriters have a 30-day option to buy up to 2,113,500 additional shares. Form 424B5 · SEC filing
Aug 20, 2026 ·
Financing Amylyx entered an underwriting agreement for a priced offering of 14,090,000 shares at $35.50 per share, with a 30-day option for 2,113,500 more. Net proceeds are about $471.7 million, or $542.5 million if the option is exercised in full. Closing is expected August 21, 2026. Form 8-K · SEC filing
Aug 18, 2026 ·
Clinical trial Announced positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia: a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003). All secondary endpoints were met, and the company plans an NDA submission by end of 2026. Form 8-K · SEC filing · Press release
Aug 18, 2026 ·
Clinical trial Amylyx reported positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia, with a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003). All secondary endpoints were also met. Form 8-K · SEC filing · Press release
Aug 18, 2026 ·
Financing Amylyx Pharmaceuticals filed a preliminary prospectus for a proposed offering of up to $350,000,000 of common stock, with Leerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital as underwriters. Amount per share is not yet set; the stock closed at $35.11 on Aug 18, 2026. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2027 · Phase 1 · Recruiting · AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis Registry primary completion date, not a results date
Jul 2026 · Phase 3 · Active Trial · Avexitide for Treatment of Post-Bariatric Hypoglycemia Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AMLX holds $768.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $32.5M/quarter from operations,
an estimated runway of 70.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:17 · Low
Cash runway 71 months
Shelf registration (S-3ASR, Mar 2026) +10
Share count +17% in a year +7
Recent financing filings on SEC EDGAR:
Aug 20, 2026 · Underwritten offering, $500M · 424B5
Share count 128,562,904 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AMLX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMLX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.